Journals / art / 2021 / Cilt: 36 - Sayı: 2

Assessment of subclinical atherosclerosis with ankle-brachial index in psoriatic arthritis: A case-control study

Journal
art
Pages
210–218
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

A Doppler probe and a standard blood pressure cuff were used to calculate theABI values for each participant.Results: Patients had lower right ABI (median, 1.05 vs. 1.1, p<0.01), lower left ABI (1.04 vs. 1.09, p<0.01) and lower overall ABI (1.03 vs. 1.09, p<0.01)compared with healthy subjects.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: This study aims to evaluate subclinical atherosclerosis using the Ankle-Brachial Index (ABI) in patients with psoriatic arthritis (PsA).Patients and methods: This case-control study included 51 PsA patients (24 males, 27 females; median age 47; range, 41 to 52 years) recruitedat our hospital’s outpatient clinics between October 2016 and January 2017 and 50 healthy controls (24 males, 26 females; median age: 48.5;range, 40.7 to 56 years).
📊
Key Findings & Data:In patients, the 66 swollen/68 tender joints count,dactylitis score, Leeds Enthesitis Index, Health-related Quality of Life, the Psoriasis Area and Severity Index, and Dermatology Life Quality Index wereevaluated.
💡
Conclusion & Impact:A Doppler probe and a standard blood pressure cuff were used to calculate theABI values for each participant.Results: Patients had lower right ABI (median, 1.05 vs. 1.1, p<0.01), lower left ABI (1.04 vs. 1.09, p<0.01) and lower overall ABI (1.03 vs. 1.09, p<0.01)compared with healthy subjects.
🔬Design:Research Article
📍Scope:2016 Verileri
⚙️Variables:Domain Parameters

Özet

Objectives: This study aims to evaluate subclinical atherosclerosis using the Ankle-Brachial Index (ABI) in patients with psoriatic arthritis (PsA).Patients and methods: This case-control study included 51 PsA patients (24 males, 27 females; median age 47; range, 41 to 52 years) recruitedat our hospital’s outpatient clinics between October 2016 and January 2017 and 50 healthy controls (24 males, 26 females; median age: 48.5;range, 40.7 to 56 years). Anthropomorphic measurements and laboratory results were recorded. In patients, the 66 swollen/68 tender joints count,dactylitis score, Leeds Enthesitis Index, Health-related Quality of Life, the Psoriasis Area and Severity Index, and Dermatology Life Quality Index wereevaluated. Ankylosing Spondylitis Quality of Life and Bath Ankylosing Spondylitis Disease Activity Index were applied to patients with axial disease.Then, Composite Psoriatic Disease Activity Index was determined. A Doppler probe and a standard blood pressure cuff were used to calculate theABI values for each participant.Results: Patients had lower right ABI (median, 1.05 vs. 1.1, p<0.01), lower left ABI (1.04 vs. 1.09, p<0.01) and lower overall ABI (1.03 vs. 1.09, p<0.01)compared with healthy subjects. Twelve (23.5%) patients had borderline ABI, but none of the controls (p<0.01). Patients with borderline ABI had alonger duration of psoriasis (25 vs. 15 years, p=0.03). The distribution of borderline ABI value was statistically significant between patients with axialdisease and peripheral disease only (42.1% vs. 12.5%, p=0.02). Disease activity was found as an independent risk factor for borderline ABI in a binarylogistic regression (odds ratio 6.306, 95% confidence interval 1.185 to 33.561, p=0.031).Conclusion: Lower ABI was found in PsA patients than healthy controls even in those matched with traditional cardiovascular risk factors. Allparticipants with borderline ABI were in the patient group. Borderline ABI was associated with disease activity and disease duration.

🔖

Cite This Article

BİLİM, S., İÇAĞASIOĞLU, A., AKBAL, A., GÜNAL, E. K., GÜRSEL, S. (2021). Assessment of subclinical atherosclerosis with ankle-brachial index in psoriatic arthritis: A case-control study. art, Cilt: 36 - Sayı: 2, 210–218. https://ajindex.com/articles/351714

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973;3:55-78
  2. Rudwaleit M, Taylor WJ. Classification criteria for psoriatic arthritis and ankylosing spondylitis/axial spondyloarthritis. Best Pract Res Clin Rheumatol 2010;24:589-604
  3. Kay L, Parry-James J, Walker D. The prevalence and impact of psoriasis in the primary care population in Northeast England. Arthritis Rheum 1999;42(9 Suppl):S299
  4. Shbeeb M, Uramoto KM, Gibson LE, O'Fallon WM, Gabriel SE. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol 2000;27:1247-50
  5. Hochberg MC, Silman AJ, Smolen JS, Weinbatt ME, Wiesman MH, editors. Rheumatology. 6th ed. Philadelphia: Mosby Elsevier; 2014
  6. Jamnitski A, Symmons D, Peters MJ, Sattar N, McInnes I, Nurmohamed MT. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis 2013;72:211-6
  7. Gladman DD, Ang M, Su L, Tom BD, Schentag CT, Farewell VT. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis 2009;68:1131-5
  8. Shang Q, Tam LS, Sanderson JE, Sun JP, Li EK, Yu CM. Increase in ventricular-arterial stiffness in patients with psoriatic arthritis. Rheumatology (Oxford) 2012;51:2215-23
  9. Di Minno MN, Iervolino S, Peluso R, Scarpa R, Di Minno G; CaRRDs study group. Carotid intima-media thickness in psoriatic arthritis: differences between tumor necrosis factor-a blockers and traditional disease-modifying antirheumatic drugs. Arterioscler Thromb Vasc Biol 2011;31:705-12
  10. Contessa C, Ramonda R, Lo Nigro A, Modesti V, Lorenzin M, Puato M, et al. Aterosclerosi subclinica in pazienti con artrite psoriasica: studio caso-controllo. Dati preliminari [Subclinical atherosclerosis in patients with psoriatic arthritis: a case-control study. Preliminary data]. Reumatismo 2009;61:298-305
  11. Kerekes G, Soltész P, Nurmohamed MT, Gonzalez- Gay MA, Turiel M, Végh E, et al. Validated methods for assessment of subclinical atherosclerosis in rheumatology. Nat Rev Rheumatol 2012;8:224-34
  12. Alkaabi JK, Ho M, Levison R, Pullar T, Belch JJ. Rheumatoid arthritis and macrovascular disease. Rheumatology (Oxford) 2003;42:292-7. 13. del Rincón I, Haas RW, Pogosian S, Escalante A. Lower limb arterial incompressibility and obstruction in rheumatoid arthritis. Ann Rheum Dis 2005;64:425-32
  13. Stamatelopoulos KS, Kitas GD, Papamichael CM, Kyrkou K, Zampeli E, Fragiadaki K, et al. Subclinical peripheral arterial disease in rheumatoid arthritis. Atherosc